R. E. Marcus - Concepedia

Author

R. E. Marcus

Addenbrooke's Hospital

Also Known As

R E Marcus, R Marcus, R. E. MARCUS, R. E. Marcus, R. Marcus, R.E Marcus, R.E. MARCUS, R.E. Marcus, RE Marcus

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Addenbrooke's Hospital Guy's Hospital John Radcliffe Hospital University of Cambridge London Postgraduate Medical and Dental Education

About

R. E. Marcus is an author at Addenbrooke's Hospital specializing in medicine, hematology, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	999
2	Health Sciences	5	5	131
3	Cellular Therapies	4	4	103
4	Blood Transplantation	3	3	110
5	Cell Biology	1	1	12

R. E. Marcus

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma R. E. Marcus Blood	2004	966
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial KM Ardeshna, Peter Smith, AJ Norton, The Lancet Lymphoid NeoplasiaLong-term EffectHealth PolicyMedicineSystemic Treatment	2003	538
A multicentre, open, non‐comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony‐stimulating factor in relapsed and refractory acute myeloid leukaemia and <i>de novo</i> refractory anaemia with excess of blasts in transformation Graham Jackson, P R Taylor, Graeme Smith, British Journal of Haematology	2001	110
Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. Michael A. Weiner, Brigid G. Leventhal, R. E. Marcus, Journal of Clinical Oncology Low-dose RadiotherapyPathologyPharmacotherapyMetronomic ChemotherapyProgressive Hodgkin	1991	78
Activity of Oral Fludarabine Phosphate in Previously Treated Chronic Lymphocytic Leukemia M. Boogaerts, Ambro van Hoof, Daniel Catovsky, Journal of Clinical Oncology	2001	69
The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients Kevin Jestice, MA Scott, D. M. Bloxham, Bone Marrow Transplantation Hematological MalignancyCell TherapyTransplantationMedicineStem Cell Mobilization	1998	62
A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants Susan A. Jebb, R. E. Marcus, M. Elia Clinical Nutrition TransplantationMarrow TransplantationStem Cell TransplantationHematologyGraft Survival	1995	60
A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group. Gerhartz Hh, R. E. Marcus, Alain Delmer, PubMed	1994	56
A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study MA Scott, H. K. Jestice, P Mahendra, Bone Marrow Transplantation Graft-versus-host DiseaseTransplantationAutoimmune DiseaseStem Cell TransplantationImmunology	1998	46
Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial Norbert Schmitz, Per Ljungman, Charlotte Cordonnier, Bone Marrow Transplantation Regenerative MedicineTransplantationMarrow TransplantationStem Cell TransplantationHematology	2004	46

Page 1